Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant.

Tachibana T, Tanaka M, Yamazaki E, Numata A, Takasaki H, Kuwabara H, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.

Leuk Lymphoma. 2013 Jun;54(6):1318-20. doi: 10.3109/10428194.2012.730613. Epub 2012 Nov 1. No abstract available.

PMID:
22989327
2.

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.

Lim ZY, Fiaccadori V, Gandhi S, Hayden J, Kenyon M, Ireland R, Marsh J, Ho AY, Mufti GJ, Pagliuca A.

Leuk Res. 2010 Jun;34(6):723-7. doi: 10.1016/j.leukres.2009.10.028. Epub 2009 Nov 26.

PMID:
19944463
3.

Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome.

Tachibana T, Takasaki H, Tanaka M, Maruta A, Hyo R, Ishigatsubo Y, Kanamori H.

Bone Marrow Transplant. 2011 Jan;46(1):150-1. doi: 10.1038/bmt.2010.62. Epub 2010 Apr 12. No abstract available.

PMID:
20383206
4.

Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies.

Tachibana T, Tanaka M, Takasaki H, Numata A, Ito S, Watanabe R, Hyo R, Ohshima R, Hagihara M, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H.

Int J Hematol. 2011 Mar;93(3):368-74. doi: 10.1007/s12185-011-0784-0. Epub 2011 Feb 18.

PMID:
21331523
5.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT)..

Haematologica. 2009 Apr;94(4):542-9. doi: 10.3324/haematol.2008.000927. Epub 2009 Mar 10.

6.

Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts.

Wahlin A, Lorenz F, Fredriksson M, Remberger M, Wahlin BE, Hägglund H.

Med Oncol. 2011 Jun;28(2):552-8. doi: 10.1007/s12032-010-9496-1.

PMID:
20393815
7.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.

Koenecke C, Göhring G, de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N; MDS subcommittee of the Chronic Malignancies Working Party of the EBMT..

Haematologica. 2015 Mar;100(3):400-8. doi: 10.3324/haematol.2014.116715. Epub 2014 Dec 31.

8.

Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.

Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M.

J Exp Clin Cancer Res. 2011 Apr 10;30:36. doi: 10.1186/1756-9966-30-36.

9.

Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk.

Tachibana T, Tanaka M, Numata A, Takasaki H, Ito S, Ohshima R, Hagihara M, Yamazaki E, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H.

Leuk Lymphoma. 2012 Mar;53(3):456-61. doi: 10.3109/10428194.2011.619607. Epub 2011 Oct 24.

PMID:
21883028
10.

Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies.

Kümpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen W, Buchholz S, Hertenstein B, Krauter J, Eder M, David S, Göhring G, Haller H, Ganser A.

Blood. 2008 Sep 1;112(5):2139-48. doi: 10.1182/blood-2007-12-130021. Epub 2008 May 15.

11.

Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome.

Chang YJ, Zhao XY, Xu LP, Liu DH, Liu KY, Chen YH, Wang Y, Zhang XH, Zhao XS, Han W, Chen H, Wang FR, Lv M, Huang XJ.

Leuk Lymphoma. 2013 Dec;54(12):2671-7. doi: 10.3109/10428194.2013.783912. Epub 2013 May 21.

PMID:
23550991
12.

Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.

Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K.

Bone Marrow Transplant. 2005 May;35(10):965-70.

PMID:
15806131
13.

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2011 Jun;17(6):852-60. doi: 10.1016/j.bbmt.2010.09.006. Epub 2010 Sep 18.

14.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
15.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.

J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.

PMID:
18086801
16.

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A.

Haematologica. 2010 Mar;95(3):476-84. doi: 10.3324/haematol.2009.011429. Epub 2009 Nov 10.

17.

Pre-transplant serum ferritin is prognostic but is it useful?

Artz AS, van Besien K.

Leuk Lymphoma. 2013 Jun;54(6):1133-4. doi: 10.3109/10428194.2012.756483. Epub 2013 Jan 8. No abstract available.

PMID:
23216268
18.

A novel differential predict model based on matrix-assisted laser ionization time-of-flight mass spectrometry and serum ferritin for acute graft-versus-host disease.

Zhang CY, Wang SH, Huang WR, Guo GH, Zhang ZH, Mou WJ, Yu L, Tian YP.

Biomed Res Int. 2013;2013:563751. doi: 10.1155/2013/563751. Epub 2013 Oct 1.

19.

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35. Epub 2007 Nov 26.

20.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.

Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS, Kang YA, Kang SI, Jeon MJ, Seol M, Seo EJ, Chi HS, Park CJ, Jang S, Yun SC, Lee KH.

Bone Marrow Transplant. 2010 Mar;45(3):450-7. doi: 10.1038/bmt.2009.190. Epub 2009 Aug 10.

PMID:
19668236

Supplemental Content

Support Center